BCC1
MCID: BSL024
MIFTS: 55

Basal Cell Carcinoma 1 (BCC1)

Categories: Cancer diseases, Genetic diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Basal Cell Carcinoma 1

MalaCards integrated aliases for Basal Cell Carcinoma 1:

Name: Basal Cell Carcinoma 1 57
Bcc1 57 29 6
Basal Cell Carcinoma, Susceptibility to, 1 57 13
Basal Cell Carcinoma 72 70
Carcinoma, Basal Cell, Susceptibility to, Type 1 39
Experimental Organism Basal Cell Carcinoma 70
Non-Syndromic Basal Cell Carcinoma 72
Basal Cell Carcinoma, Multiple 70
Multiple Basal Cell Carcinoma 72
Carcinoma, Basal Cell 44
Bcc 72

Classifications:



External Ids:

OMIM® 57 605462
MeSH 44 D002280
SNOMED-CT via HPO 68 1338007 254701007 275265005
UMLS 70 C0007117 C1854245 C3811653

Summaries for Basal Cell Carcinoma 1

OMIM® : 57 Cutaneous basal cell carcinoma (BCC) is the most common cancer among people of European ancestry (Stacey et al., 2009). The primary environmental risk factor for BCC is sun exposure, but genetics also has a substantial role. Some of the sequence variants that confer susceptibility seem to operate through their association with fair-pigmentation traits common among Europeans, resulting in reduced protection from the damaging effects of ultraviolet (UV) radiation. Other sequence variants have no obvious role in pigmentation or UV susceptibility but instead seem to operate in the contexts of growth and differentiation of the basal layers of the skin (Stacey et al., 2008; Epstein, 2008; Gudbjartsson et al., 2008; Rafnar et al., 2009). See ASIP (600201), TYR (606933), and SHEP5 (227240) for examples of basal cell carcinoma associated with fair skin or sensitivity to sun. Basal cell carcinoma occurs as a feature of multiple syndromes, including basal cell nevus syndrome (BCNS; 109400), Bazex syndrome (301845), Rombo syndrome (180730), Brooke-Spiegler syndrome (605041), Muir-Torre syndrome (158320), and xeroderma pigmentosum (see 278700). Abnormalities in the Hedgehog signaling pathway are found in basal cell carcinomas; see SHH (600725) and SMOH (601500). (605462) (Updated 20-May-2021)

MalaCards based summary : Basal Cell Carcinoma 1, also known as bcc1, is related to basal cell nevus syndrome and basal cell carcinoma, multiple. An important gene associated with Basal Cell Carcinoma 1 is PTCH1 (Patched 1), and among its related pathways/superpathways are Pathways in cancer and G-protein signaling G-Protein alpha-i signaling cascades. The drugs Fluorouracil and Triamcinolone have been mentioned in the context of this disorder. Affiliated tissues include skin, prostate and kidney, and related phenotypes are basal cell carcinoma and digestive/alimentary

UniProtKB/Swiss-Prot : 72 Basal cell carcinoma: A common malignant skin neoplasm that typically appears on hair- bearing skin, most commonly on sun-exposed areas. BCC is slow growing and rarely metastasizes, but has potentialities for local invasion and destruction. It usually develops as a flat, firm, pale area that is small, raised, pink or red, translucent, shiny, and waxy, and the area may bleed following minor injury. Tumor size can vary from a few millimeters to several centimeters in diameter.

Related Diseases for Basal Cell Carcinoma 1

Diseases in the Small Cell Carcinoma family:

Basal Cell Carcinoma 1 Basal Cell Carcinoma 2
Basal Cell Carcinoma 3 Basal Cell Carcinoma 4
Basal Cell Carcinoma 5 Basal Cell Carcinoma 6
Basal Cell Carcinoma 7 Basal Cell Carcinoma
Large Cell Carcinoma Basal Cell Carcinoma, Multiple

Diseases related to Basal Cell Carcinoma 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 621)
# Related Disease Score Top Affiliating Genes
1 basal cell nevus syndrome 31.9 SMO PTCH2 PTCH1 LOC100507346
2 basal cell carcinoma, multiple 31.8 RASA1 PTCH1 LOC100507346 CCNH
3 focal dermal hypoplasia 30.9 PTCH2 PTCH1
4 keratocystic odontogenic tumor 30.4 SMO PTCH1
5 ameloblastoma 30.3 SMO PTCH1
6 weber syndrome 30.1 RASA1 CCNH
7 basal cell carcinoma 30.0 SMO RASA1 PTCH2 PTCH1 BCC1
8 congenital hydrocephalus 30.0 PTCH1 LOC100507346
9 medulloblastoma 29.9 SMO PTCH2 PTCH1 LOC100507346
10 arteriovenous malformation 29.8 RASA1 CCNH
11 overgrowth syndrome 29.8 PTCH1 LOC100507346
12 nodular medulloblastoma 29.7 PTCH2 PTCH1
13 skin carcinoma 28.7 SMO PTCH2 PTCH1
14 nodular basal cell carcinoma 11.8
15 basal cell carcinoma, infundibulocystic 11.8
16 basal cell carcinoma 7 11.7
17 superficial basal cell carcinoma 11.7
18 pigmented basal cell carcinoma 11.7
19 metatypical basal cell carcinoma 11.7
20 micronodular basal cell carcinoma 11.6
21 anal margin basal cell carcinoma 11.6
22 penis basal cell carcinoma 11.6
23 morpheaform basal cell carcinoma 11.6
24 cystic basal cell carcinoma 11.5
25 adenoid basal cell carcinoma 11.5
26 sarcomatoid basal cell carcinoma 11.5
27 clear cell basal cell carcinoma 11.5
28 basal cell carcinoma 2 11.5
29 basal cell carcinoma 5 11.5
30 basal cell carcinoma 3 11.5
31 basal cell carcinoma 6 11.5
32 vulva basal cell carcinoma 11.5
33 basal cell carcinoma 4 11.5
34 external ear basal cell carcinoma 11.5
35 signet ring basal cell carcinoma 11.5
36 vulvar basal cell carcinoma 11.5
37 infiltrative basal cell carcinoma 11.5
38 follicular basal cell carcinoma 11.5
39 scrotum basal cell carcinoma 11.5
40 fibroepithelial basal cell carcinoma 11.4
41 bazex syndrome 11.3
42 adamantinoid basal cell epithelioma 11.3
43 sebaceous basal cell carcinoma 11.3
44 squamous cell carcinoma 11.3
45 trichoepithelioma, multiple familial, 1 11.2
46 9q22.3 microdeletion 11.2
47 inflammatory linear verrucous epidermal nevus 11.1
48 clear cell acanthoma 11.1
49 bap1 tumor predisposition syndrome 11.1
50 epidermolysis bullosa simplex, dowling-meara type 11.1

Graphical network of the top 20 diseases related to Basal Cell Carcinoma 1:



Diseases related to Basal Cell Carcinoma 1

Symptoms & Phenotypes for Basal Cell Carcinoma 1

Human phenotypes related to Basal Cell Carcinoma 1:

31
# Description HPO Frequency HPO Source Accession
1 basal cell carcinoma 31 HP:0002671

Clinical features from OMIM®:

605462 (Updated 20-May-2021)

MGI Mouse Phenotypes related to Basal Cell Carcinoma 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 8.92 PTCH1 PTCH2 RASA1 SMO

Drugs & Therapeutics for Basal Cell Carcinoma 1

Drugs for Basal Cell Carcinoma 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 191)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluorouracil Approved Phase 4 51-21-8 3385
2
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
3
Imiquimod Approved, Investigational Phase 4 99011-02-6 57469
4 Triamcinolone hexacetonide Phase 4
5 Triamcinolone diacetate Phase 4
6 triamcinolone acetonide Phase 4
7 Tin Fluorides Phase 4
8 Antiviral Agents Phase 4
9 Interferon-alpha Phase 4
10 polysaccharide-K Phase 4
11
Aminolevulinic acid Approved Phase 3 106-60-5 137
12
Verteporfin Approved, Investigational Phase 3 129497-78-5
13
Tretinoin Approved, Investigational, Nutraceutical Phase 3 302-79-4 5538 444795
14 Photosensitizing Agents Phase 3
15 Dermatologic Agents Phase 3
16 Tea Phase 2, Phase 3
17 Veratrum Alkaloids Phase 3
18 Antihypertensive Agents Phase 3
19 Methyl 5-aminolevulinate Phase 3
20
Arsenic trioxide Approved, Investigational Phase 1, Phase 2 1327-53-3 518740
21
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
22
Diclofenac Approved, Vet_approved Phase 2 15307-86-5 3033
23
Cetuximab Approved Phase 1, Phase 2 205923-56-4 56842117 2333
24
Bevacizumab Approved, Investigational Phase 2 216974-75-3
25
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
26
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
27
leucovorin Approved Phase 2 58-05-9 6006
28
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
29
Ipilimumab Approved Phase 2 477202-00-9
30
nivolumab Approved Phase 2 946414-94-4
31
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
32
Nicotinamide Approved, Investigational Phase 2 98-92-0 936
33
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
34
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
35
Cemiplimab Approved, Investigational Phase 2 1801342-60-8
36
Benzoic acid Approved, Investigational Phase 2 65-85-0 243
37
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
38
Fluoxymesterone Approved, Illicit Phase 1, Phase 2 76-43-7 6446
39
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
40
Etoposide Approved Phase 2 33419-42-0 36462
41
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
42
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
43
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
44
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
45
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
46
Calcitriol Approved, Nutraceutical Phase 2 32222-06-3 134070 5280453
47
Aspartic acid Approved, Nutraceutical Phase 1, Phase 2 56-84-8 5960
48
Glycine Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 56-40-6 750
49
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
50
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 252)
# Name Status NCT ID Phase Drugs
1 Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma Unknown status NCT00803907 Phase 4 Imiquimod 5% cream
2 Treatment of Superficial Basal Cell Carcinoma by Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Topical Photodynamic Therapy With Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
3 CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial Completed NCT00847912 Phase 4 5-fluorouracil;Placebo, vehicle control
4 A Randomized Open Label Study to Evaluate the Safety and Efficacy if Imiquimod 5% Cream Applied 3 Times Per Week for 8 or 12 Weeks in the Treatment of Low Risk Nodular Basal Cell Carcinoma Completed NCT00204555 Phase 4 Imiquimod
5 Intron-A/Aldara Combination Therapy for BCC Excluding the Face and Scalp Completed NCT00581425 Phase 4
6 Topical Imiquimod 5% Cream in the Treatment of Nodular Basal Cell Carcinoma After Initial Treatment With Curettage Completed NCT00314756 Phase 4 imiquimod
7 Study of the Relationship Between the Pharmacokinetics of Vismodegib and Safety Data: a Pilot Study to Therapeutic Optimization in Patients With Basal Cell Carcinoma - OPTIVISMO-1 Recruiting NCT03610022 Phase 4 Treatment with vismodegib
8 VISmodegib for ORbital and Periocular Basal Cell Carcinoma (VISORB) Active, not recruiting NCT02436408 Phase 4 Vismodegib
9 A Randomized Clinical Trial in the Surgical Treatment of Basal Cell Carcinoma of the Eyelid: Surgical Excision With Frozen Section vs. Permanent Section Control Unknown status NCT00663650 Phase 3
10 Open Label, Randomized Comparison of Two Schemes of Cryosurgery and Imiquimod Combination Treatment for Basal Cell Carcinoma of the Skin Completed NCT01212549 Phase 3
11 Topical Sinecatechins Ointment in Treatment of Primary Superficial Basal Cell Carcinoma: a Double Blind, Randomized, Placebo-controlled Trial. Completed NCT02029352 Phase 2, Phase 3 Sinecatechins 10%;Placebo
12 Open Study to Evaluate the Efficacy and Tolerance of Imiquimod 5% Cream for the Treatment of a Large and/or Multiple Superficial Basal Cell Carcinoma. Completed NCT00189280 Phase 3 Imiquimod
13 A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) in Comparison to Metvix® in the Treatment of Non-aggressive Basal Cell Carcinoma (BCC) With Photodynamic Therapy (PDT) Completed NCT02144077 Phase 3 BF-200 ALA;methyl-aminolevulinate
14 A Multicentre, Phase III, Double Blind Study of Photodynamic Therapy (PDT) With Metvix® 160 mg/g Cream in Comparison to PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma. Completed NCT00472043 Phase 3
15 A Multicenter, Phase III, Randomised Study of Photodynamic Therapy With Metvix Cream 160 mg/g in Comparison With Cryotherapy in Patients With Primary Superficial Basal Cell Carcinoma Completed NCT00469417 Phase 3
16 An Open-label Study to Evaluate the Safety and Long-Term Clinical Efficacy of Imiquimod 5% Cream Applied Once Daily 7 Days Per Week for 6 Weeks in the Treatment of Superficial Basal Cell Carcinoma Completed NCT00189306 Phase 3 Imiquimod 5% cream
17 An Open-Label Study to Evaluate the Safety and Long-Term Clinical Efficacy of Imiquimod 5% Cream Applied Once Daily 5 Days Per Week for 6 Weeks in the Treatment of Superficial Basal Cell Carcinoma Completed NCT00189241 Phase 3 imiquimod
18 Open-label Study to Evaluate the Use of Imiquimod 5% Cream for Reducing Postsurgical Recurrence or Persistence of Basal Cell Carcinoma Following Excision by Curettage Completed NCT00129519 Phase 3 Imiquimod 5% cream
19 An Open Multicenter, Phase III Study of Photodynamic Therapy With Metvix Cream 160 mg/g in Patients With "High Risk" Basal Cell Carcinoma Completed NCT00473343 Phase 3
20 A Multicenter, Phase III, Double Blind Study of Photodynamic Therapy (PDT) With Metvix 160 mg/g Cream in Comparison to PDT With Placebo Cream in Patients With Primary Nodular Basal Cell Carcinoma Completed NCT00472108 Phase 3
21 A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome Completed NCT03703310 Phase 3 Patidegib Topical Gel, 2%;Patidegib Topical Gel, Vehicle
22 CSP #402 - VA Topical Tretinoin Chemoprevention Trial Completed NCT00007631 Phase 3 Tretinoin 0.1% cream or placebo
23 A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma Completed NCT00066872 Phase 3 imiquimod
24 Conventional Versus Fractional CO2 Laser Assisted Photodynamic Therapy for Basal Call Carcinomas and Actinic Keratoses Completed NCT01260987 Phase 2, Phase 3 Conventional photodynamic therapy;Fractional CO2 laser assisted PDT
25 A Multicentre, Randomised Study of Photodynamic Therapy(PDT) With Metvix® 160 mg/g Cream in Immuno-compromised Patients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
26 A Randomized, Double Blind, Vehicle-controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT). Recruiting NCT03573401 Phase 3
27 Surgical Excision Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma: an Open, Non-inferiority, Randomized Controlled Trial Active, not recruiting NCT02242929 Phase 3 Imiquimod 5% cream with prior curettage
28 A Randomized, Placebo-Controlled, Masked, Multicenter Phase III Study Of Photodynamic Therapy With Verteporfin For Injection (VFI) For The Treatment Of Multiple Basal Cell Carcinoma Terminated NCT00049959 Phase 3 verteporfin PDT
29 A Randomized, Double-blind, Vehicle-controlled, Multicenter Trial of Topically Administered LDE225 Cream (0.75% Bid) to Evaluate Clearance of Basal Cell Carcinoma in Adult Patients With Nevoid Basal Cell Carcinoma Syndrome Withdrawn NCT03070691 Phase 2, Phase 3 LDE225B;Vehicle
30 Open, Prospective, Single-center Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma Unknown status NCT03546166 Phase 2 Picato 0.05% Topical Gel
31 A Phase II, Single-armed, Multicenter Trial of Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma Unknown status NCT03035188 Phase 2 Vismodegib
32 Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight Unknown status NCT01349361 Phase 2
33 Investigation of the Effectiveness of Non-Coherent Blue Light in Intralesional Photodynamic of Basal Cell Carcinoma Unknown status NCT00747903 Phase 2 aminolevulinic acid hydrochloride
34 Evaluation of Efficacy of Photodynamic Therapy in Basal Cell Carcinoma With 6 Months Follow-up Completed NCT00988455 Phase 1, Phase 2
35 Phase IIb Open-label Trial of SUBA™-Itraconazole in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS) Completed NCT02354261 Phase 2 SUBA-Itraconazole
36 A Multi-Center, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study to Determine the Safety of PEP005 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 & 2 or Day 1 & 8 Applications to Superficial Basal Cell Carcinoma Completed NCT00108134 Phase 2 PEP005
37 A Multi-center, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Determine the Safety of PEP005 0.0025%, 0.01% and 0.05% Gel With Two Treatment Schedules, Day 1 & 2 or Day 1 & 8 Applications to Nodular Basal Cell Carcinoma Completed NCT00108121 Phase 2 PEP005
38 A Randomized, Double-blinded, Regimen-controlled, Phase II, Multicenter Study to Assess the Efficacy and Safety of Two Different Vismodegib Regimens in Patients With Multiple Basal Cell Carcinomas Completed NCT01815840 Phase 2 Vismodegib;Placebo
39 A Phase II Randomized, Open Label Trial Comparing the Effects of Intermittent Vismodegib Versus PDT on the Maintenance of Benefit Following 7 Months of Continuous Vismodegib Treatment in Patients With Multiple Basal Cell Carcinomas Completed NCT01556009 Phase 2 Vismodegib;Aminolevulinic acid %20 topical solution
40 Investigation of Local Skin Reactions and Safety After Combined Treatment of Basal Cell Carcinoma Using Ablative Fractional Laser and Ingenol Mebutate - an Exploratory, Prospective, Open-label Phase 2a Trial. Completed NCT03569345 Phase 1, Phase 2 AFXl-assisted ingenol mebutate delivery
41 Tolerability of Laser-assisted Cisplatin + 5-fluorouracil- an Exploratory Proof of Concept Study of Topical Combination Chemotherapy for Basal Cell Carcinoma Completed NCT03541252 Phase 1, Phase 2 AFL-assisted cisplatin+5-FU
42 ML28485:Phase 2B Single-site,Open-label,Nonrandomized Study Evaluating Efficacy of Oral Vismodegib in Various Histologic Subtypes (Infiltrative/Morpheaform,Nodular and Superficial)of High Risk and/or Locally Advanced Basal Cell Carcinoma Completed NCT01700049 Phase 2 vismodegib (150 mg PO daily)
43 Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients With Basal Cell Carcinomas Completed NCT01108094 Phase 2 Itraconazole
44 Photochemical Tissue Bonding (PTB) for Excisional Wound Healing Completed NCT00586040 Phase 2
45 A Pivotal Phase II, Multicenter, Single-arm, Two-cohort Trial Evaluating the Efficacy and Safety of GDC-0449 in Patients With Advanced Basal Cell Carcinoma Completed NCT00833417 Phase 2 Vismodegib 150 mg
46 Phase IIa Trial With PD-L1 IO103 Vaccination With Montanide in Patients With Basal Cell Carcinoma Completed NCT03714529 Phase 2
47 A Phase 1b Open Label Study of Pembrolizumab for Unresectable or Metastatic Basal Cell Carcinoma Completed NCT02690948 Phase 1, Phase 2 Vismodegib
48 Topical Vitamin D3, Diclofenac or a Combination of Both to Treat Basal Cell Carcinoma Completed NCT01358045 Phase 2 Diclofenac;Diclofenac + Calcitriol;Calcitriol
49 A Phase II, Double-blind, Randomized, Proof-of-Concept, Dose-ranging Trial Evaluating the Efficacy, Safety and Pharmacokinetics of Oral LDE225 in Treatment of Adult Patients With Nevoid Basal Cell Carcinoma Syndrome Completed NCT01350115 Phase 2 LDE225;Placebo
50 Placebo-controlled, Double Blind Study to Assess Efficacy and Safety of Oral Vismodegib for the Treatment of Basal Cell Carcinoma Preceding Excision by Mohs Micrographic Surgery (MMS) Completed NCT01543581 Phase 2 Vismodegib;Placebo

Search NIH Clinical Center for Basal Cell Carcinoma 1

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Fluorouracil

Cochrane evidence based reviews: carcinoma, basal cell

Genetic Tests for Basal Cell Carcinoma 1

Genetic tests related to Basal Cell Carcinoma 1:

# Genetic test Affiliating Genes
1 Bcc1 29 PTCH1 PTCH2 RASA1 SMO

Anatomical Context for Basal Cell Carcinoma 1

MalaCards organs/tissues related to Basal Cell Carcinoma 1:

40
Skin, Prostate, Kidney, Thyroid, Endothelial, Eye, Brain

Publications for Basal Cell Carcinoma 1

Articles related to Basal Cell Carcinoma 1:

(show top 50) (show all 54)
# Title Authors PMID Year
1
A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy. 57
30297799 2018
2
A cell identity switch allows residual BCC to survive Hedgehog pathway inhibition. 57
30297801 2018
3
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. 57
19726763 2009
4
New common variants affecting susceptibility to basal cell carcinoma. 57
19578363 2009
5
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. 57
19151717 2009
6
Common variants on 1p36 and 1q42 are associated with cutaneous basal cell carcinoma but not with melanoma or pigmentation traits. 57
18849993 2008
7
Basal cell carcinomas: attack of the hedgehog. 57
18813320 2008
8
Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/beta3-catenin signaling. 57
19165927 2008
9
ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. 57
18488027 2008
10
Cutaneous basal cell carcinomas: distinct host factors are associated with the development of tumors on the trunk and on the head and neck. 57
11466690 2001
11
Nonsyndromic type of hereditary multiple basal cell carcinoma. 57
11078568 2000
12
Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. 57
9931336 1999
13
Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. 57
9620294 1998
14
The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. 57
8782823 1996
15
Nonsense mutations in the C-terminal SH2 region of the GTPase activating protein (GAP) gene in human tumours. 57
8275088 1993
16
Value of Teledermoscopy in Primary Healthcare Centers: Preliminary Results of the TELESPOT Project in Belgium. 61
32946049 2020
17
Theoretical and Experimental Studies of the Structural, Phase Stability and Elastic Properties of AlCrTiFeNi Multi-Principle Element Alloy. 61
33007907 2020
18
Exploratory Assessment of Oxygen Flow-Assisted Cutaneous Administration of Methotrexate for Superficial Basal Cell Carcinoma, Mycosis Fungoides, and Extramammary Paget Disease. 61
31513804 2020
19
BCc1 Nanomedicine Therapeutic Effects in Streptozotocin and High-Fat Diet Induced Diabetic Kidney Disease. 61
32368111 2020
20
β-Aminopeptidases: Insight into Enzymes without a Known Natural Substrate. 61
31126950 2019
21
A randomized, double-blind, placebo-controlled investigation of BCc1 nanomedicine effect on survival and quality of life in metastatic and non-metastatic gastric cancer patients. 61
30971278 2019
22
Effects of BCc1 nanoparticle and its mixture with doxorubicin on survival of murine 4T1 tumor model. 61
31354301 2019
23
Evaluation of Immunohistochemical Findings and Clinical Features Associated with Local Aggressiveness in Basal Cell Carcinoma. 61
31582995 2019
24
Understanding the functions of endogenous DOF transcript factor in Chlamydomonas reinhardtii. 61
30972144 2019
25
Graviola (Annona muricata) Exerts Anti-Proliferative, Anti-Clonogenic and Pro-Apoptotic Effects in Human Non-Melanoma Skin Cancer UW-BCC1 and A431 Cells In Vitro: Involvement of Hedgehog Signaling. 61
29914183 2018
26
Orbitofacial Metastatic Basal Cell Carcinoma: Report of 10 Cases. 61
27218810 2017
27
TiZrNbTaMo high-entropy alloy designed for orthopedic implants: As-cast microstructure and mechanical properties. 61
28183676 2017
28
BCc1, the novel antineoplastic nanocomplex, showed potent anticancer effects in vitro and in vivo. 61
26766901 2016
29
Cancer Screening of Renal Transplant Patients Undergoing Long-Term Immunosuppressive Therapy. 61
26093731 2015
30
Reconstruction of scalp wounds with exposed calvarium using a local flap and a split-thickness skin graft: case series of 20 patients. 61
24438208 2014
31
Statistical analysis of high frequency ultrasonic backscattered signals from basal cell carcinomas. 61
22920547 2012
32
Cutaneous manifestations in renal transplant recipients of Santiago, Chile. 61
19917380 2009
33
Identification of a Keratin 4 mutation in a chemically induced mouse mutant that models white sponge nevus. 61
16858417 2007
34
Analysis of clonality and HPV infection in benign, hyperplastic, premalignant, and malignant lesions of the vulvar mucosa. 61
15323144 2004
35
Isolation (from a basal cell carcinoma) of a functionally distinct fibroblast-like cell type that overexpresses Ptch. 61
11982765 2002
36
Interaction between bcl-2 and P53 in neoplastic progression of basal cell carcinoma of the head and neck. 61
11911244 2001
37
P53 and hMSH2 expression in basal cell carcinomas and malignant melanomas from photoexposed areas of head and neck region. 61
11494035 2001
38
DNA ploidy and cyclin D1 expression in basal cell carcinoma of the head and neck. 61
11392875 2001
39
Prognostic value of apoptotic index in cutaneous basal cell carcinomas of head and neck. 61
10705087 1999
40
Maggot therapy for the treatment of intractable wounds. 61
10487456 1999
41
Immunohistochemical distinction of ocular sebaceous carcinoma from basal cell and squamous cell carcinoma. 61
10369589 1999
42
Cutaneous infiltrate of chronic lymphocytic leukemia and relationship to primary cutaneous epithelial neoplasms. 61
9550315 1998
43
The role of stereotactic radiosurgery in the treatment of malignant skull base tumors. 61
9392534 1997
44
Modulation of the ER Ca2+ channel BCC1 from tendrils of Bryonia dioica by divalent cations, protons and H2O2. 61
9166905 1997
45
A preliminary pharmacokinetic study of intravenous Photofrin in patients. 61
9612197 1996
46
The prognostic significance of tumor angiogenesis in nonaggressive and aggressive basal cell carcinoma of the human skin. 61
8698314 1996
47
p53 protein in aggressive and non-aggressive basal cell carcinoma. 61
7507946 1993
48
Verrucous cysts: histopathologic characterization and molecular detection of human papillomavirus-specific DNA. 61
8300926 1993
49
[A nasal reconstruction via the expansion of the tissue]. 61
8165892 1993
50
Nucleolar organizer regions in aggressive and nonaggressive basal cell carcinoma of the skin. 61
1727656 1992

Variations for Basal Cell Carcinoma 1

ClinVar genetic disease variations for Basal Cell Carcinoma 1:

6 (show all 39)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 RASA1 , CCNH NM_002890.3(RASA1):c.656C>G (p.Ser219Ter) SNV Pathogenic 464870 rs1554044823 GRCh37: 5:86627281-86627281
GRCh38: 5:87331464-87331464
2 RASA1 , CCNH NM_002890.3(RASA1):c.2131C>T (p.Arg711Ter) SNV Pathogenic 213660 rs863223718 GRCh37: 5:86672329-86672329
GRCh38: 5:87376512-87376512
3 PTCH1 NM_000264.5(PTCH1):c.938C>G (p.Ser313Ter) SNV Pathogenic 576491 rs1564055259 GRCh37: 9:98242679-98242679
GRCh38: 9:95480397-95480397
4 PTCH1 , LOC100507346 NM_000264.5(PTCH1):c.2380C>T (p.Gln794Ter) SNV Pathogenic 931311 GRCh37: 9:98229578-98229578
GRCh38: 9:95467296-95467296
5 RASA1 , CCNH NM_002890.3(RASA1):c.2925+1G>A SNV Likely pathogenic 931156 GRCh37: 5:86682721-86682721
GRCh38: 5:87386904-87386904
6 PTCH1 NM_000264.5(PTCH1):c.3090_3091insGTG (p.Phe1031_Ile1032insVal) Insertion Likely pathogenic 983117 GRCh37: 9:98220372-98220373
GRCh38: 9:95458090-95458091
7 PTCH2 NM_003738.5(PTCH2):c.2716G>C (p.Glu906Gln) SNV Uncertain significance 952970 GRCh37: 1:45292420-45292420
GRCh38: 1:44826748-44826748
8 PTCH1 NM_000264.5(PTCH1):c.37C>G (p.Arg13Gly) SNV Uncertain significance 188208 rs779791579 GRCh37: 9:98270607-98270607
GRCh38: 9:95508325-95508325
9 PTCH1 NM_000264.5(PTCH1):c.181G>A (p.Ala61Thr) SNV Uncertain significance 409215 rs150069331 GRCh37: 9:98270463-98270463
GRCh38: 9:95508181-95508181
10 PTCH1 NM_000264.5(PTCH1):c.412C>T (p.Arg138Cys) SNV Uncertain significance 486174 rs139535966 GRCh37: 9:98248139-98248139
GRCh38: 9:95485857-95485857
11 PTCH1 NM_000264.5(PTCH1):c.901G>A (p.Asp301Asn) SNV Uncertain significance 524544 rs767601899 GRCh37: 9:98242716-98242716
GRCh38: 9:95480434-95480434
12 PTCH1 NM_000264.5(PTCH1):c.949C>T (p.Leu317Phe) SNV Uncertain significance 578248 rs1380199153 GRCh37: 9:98242369-98242369
GRCh38: 9:95480087-95480087
13 PTCH1 NM_000264.5(PTCH1):c.1138G>A (p.Glu380Lys) SNV Uncertain significance 409137 rs772903899 GRCh37: 9:98241359-98241359
GRCh38: 9:95479077-95479077
14 PTCH1 , LOC100507346 NM_000264.5(PTCH1):c.1989G>C (p.Gln663His) SNV Uncertain significance 237462 rs753002023 GRCh37: 9:98231294-98231294
GRCh38: 9:95469012-95469012
15 PTCH1 , LOC100507346 NM_000264.5(PTCH1):c.2287G>T (p.Val763Phe) SNV Uncertain significance 524507 rs544963328 GRCh37: 9:98229671-98229671
GRCh38: 9:95467389-95467389
16 PTCH1 , LOC100507346 NM_000264.5(PTCH1):c.2440A>C (p.Asn814His) SNV Uncertain significance 188150 rs754623561 GRCh37: 9:98229518-98229518
GRCh38: 9:95467236-95467236
17 PTCH1 NM_000264.5(PTCH1):c.2635G>A (p.Asp879Asn) SNV Uncertain significance 216378 rs750373573 GRCh37: 9:98224206-98224206
GRCh38: 9:95461924-95461924
18 PTCH1 NM_000264.5(PTCH1):c.2671G>A (p.Gly891Ser) SNV Uncertain significance 220717 rs570091335 GRCh37: 9:98224170-98224170
GRCh38: 9:95461888-95461888
19 PTCH1 NM_000264.5(PTCH1):c.3575G>A (p.Arg1192His) SNV Uncertain significance 486183 rs762040036 GRCh37: 9:98211580-98211580
GRCh38: 9:95449298-95449298
20 PTCH1 NM_000264.5(PTCH1):c.3734A>G (p.Gln1245Arg) SNV Uncertain significance 409208 rs767792734 GRCh37: 9:98211421-98211421
GRCh38: 9:95449139-95449139
21 PTCH1 NM_000264.5(PTCH1):c.3908G>T (p.Arg1303Leu) SNV Uncertain significance 524547 rs779365332 GRCh37: 9:98209630-98209630
GRCh38: 9:95447348-95447348
22 PTCH1 NM_000264.5(PTCH1):c.3919C>T (p.Pro1307Ser) SNV Uncertain significance 132753 rs574880967 GRCh37: 9:98209619-98209619
GRCh38: 9:95447337-95447337
23 PTCH1 NM_000264.5(PTCH1):c.4024C>T (p.Arg1342Cys) SNV Uncertain significance 409167 rs781539921 GRCh37: 9:98209514-98209514
GRCh38: 9:95447232-95447232
24 PTCH1 NM_000264.5(PTCH1):c.4043A>G (p.Asn1348Ser) SNV Uncertain significance 220391 rs371943557 GRCh37: 9:98209495-98209495
GRCh38: 9:95447213-95447213
25 PTCH1 NM_000264.5(PTCH1):c.4049G>A (p.Arg1350Gln) SNV Uncertain significance 577136 rs978722722 GRCh37: 9:98209489-98209489
GRCh38: 9:95447207-95447207
26 PTCH1 NM_000264.5(PTCH1):c.4051A>G (p.Asn1351Asp) SNV Uncertain significance 188148 rs786204103 GRCh37: 9:98209487-98209487
GRCh38: 9:95447205-95447205
27 PTCH1 NM_000264.5(PTCH1):c.3337C>T (p.Arg1113Cys) SNV Uncertain significance 823625 rs758520331 GRCh37: 9:98215872-98215872
GRCh38: 9:95453590-95453590
28 PTCH1 NM_000264.5(PTCH1):c.68C>A (p.Ala23Asp) SNV Uncertain significance 930926 GRCh37: 9:98270576-98270576
GRCh38: 9:95508294-95508294
29 PTCH2 NM_003738.5(PTCH2):c.3185T>G (p.Val1062Gly) SNV Uncertain significance 931578 GRCh37: 1:45288987-45288987
GRCh38: 1:44823315-44823315
30 PTCH1 NM_000264.5(PTCH1):c.4178C>T (p.Pro1393Leu) SNV Uncertain significance 931606 GRCh37: 9:98209360-98209360
GRCh38: 9:95447078-95447078
31 PTCH1 NM_000264.5(PTCH1):c.1067+5G>C SNV Uncertain significance 237448 rs372657547 GRCh37: 9:98242246-98242246
GRCh38: 9:95479964-95479964
32 PTCH2 NM_003738.5(PTCH2):c.3347C>T (p.Pro1116Leu) SNV Uncertain significance 453938 rs539161089 GRCh37: 1:45288751-45288751
GRCh38: 1:44823079-44823079
33 PTCH2 NM_003738.5(PTCH2):c.565C>G (p.Leu189Val) SNV Uncertain significance 524558 rs747885797 GRCh37: 1:45297430-45297430
GRCh38: 1:44831758-44831758
34 PTCH2 NM_003738.5(PTCH2):c.109C>T (p.Arg37Cys) SNV Uncertain significance 570977 rs768246990 GRCh37: 1:45307675-45307675
GRCh38: 1:44842003-44842003
35 PTCH2 NM_003738.5(PTCH2):c.19C>G (p.Leu7Val) SNV Uncertain significance 453931 rs1030456781 GRCh37: 1:45308586-45308586
GRCh38: 1:44842914-44842914
36 PTCH1 NM_000264.5(PTCH1):c.4162G>A (p.Gly1388Arg) SNV Uncertain significance 135105 rs587778631 GRCh37: 9:98209376-98209376
GRCh38: 9:95447094-95447094
37 PTCH1 NM_000264.5(PTCH1):c.4138G>A (p.Ala1380Thr) SNV Uncertain significance 577111 rs111481152 GRCh37: 9:98209400-98209400
GRCh38: 9:95447118-95447118
38 PTCH1 NM_000264.5(PTCH1):c.37C>T (p.Arg13Cys) SNV Uncertain significance 930369 GRCh37: 9:98270607-98270607
GRCh38: 9:95508325-95508325
39 PTCH1 NM_001083602.3(PTCH1):c.-348T>C SNV Uncertain significance 930744 GRCh37: 9:98279101-98279101
GRCh38: 9:95516819-95516819

UniProtKB/Swiss-Prot genetic disease variations for Basal Cell Carcinoma 1:

72
# Symbol AA change Variation ID SNP ID
1 PTCH1 p.Arg1114Trp VAR_007847 rs587776689

Cosmic variations for Basal Cell Carcinoma 1:

9 (show top 50) (show all 3424)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM84510986 ZNF276 skin,NS,carcinoma,basal cell carcinoma c.*940C>T p.? 16:89739186-89739186 6
2 COSM149268805 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1261G>A p.G421R 16:72958885-72958885 6
3 COSM87274302 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1655C>T p.S552F 16:72958491-72958491 6
4 COSM87270496 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.10847C>T p.S3616F 16:72787429-72787429 6
5 COSM149259613 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.10847C>T p.S3616F 16:72787429-72787429 6
6 COSM149268792 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.5825G>A p.G1942E 16:72796857-72796857 6
7 COSM87274307 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1261G>A p.G421R 16:72958885-72958885 6
8 COSM149268800 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1655C>T p.S552F 16:72958491-72958491 6
9 COSM87273325 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.2084C>T p.P695L 16:72958062-72958062 6
10 COSM149304906 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1991C>T p.S664F 16:72958155-72958155 6
11 COSM87296537 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.11050G>A p.D3684N 16:72787226-72787226 6
12 COSM102023150 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.-23-7526C>T p.? 16:72958491-72958491 6
13 COSM102023155 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.-23-7920G>A p.? 16:72958885-72958885 6
14 COSM102019420 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.8105C>T p.S2702F 16:72787429-72787429 6
15 COSM149331772 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.11050G>A p.D3684N 16:72787226-72787226 6
16 COSM102023144 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.3083G>A p.G1028E 16:72796857-72796857 6
17 COSM102047764 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.8308G>A p.D2770N 16:72787226-72787226 6
18 COSM87286441 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.1991C>T p.S664F 16:72958155-72958155 6
19 COSM102036925 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.-23-7190C>T p.? 16:72958155-72958155 6
20 COSM149266372 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.2084C>T p.P695L 16:72958062-72958062 6
21 COSM102022243 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.-23-7097C>T p.? 16:72958062-72958062 6
22 COSM87274293 ZFHX3 skin,NS,carcinoma,basal cell carcinoma c.5825G>A p.G1942E 16:72796857-72796857 6
23 COSM104882801 XPO1 skin,NS,carcinoma,basal cell carcinoma c.782G>A p.R261Q 2:61496985-61496985 6
24 COSM104236272 XPO1 skin,NS,carcinoma,basal cell carcinoma c.782G>A p.R261Q 2:61496985-61496985 6
25 COSM101976974 XPO1 skin,NS,carcinoma,basal cell carcinoma c.782G>A p.R261Q 2:61496985-61496985 6
26 COSM87040659 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 6
27 COSM101179498 TSC2 skin,NS,carcinoma,basal cell carcinoma c.1913C>T p.S638F 16:2071897-2071897 6
28 COSM150324396 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 6
29 COSM101191558 TSC2 skin,NS,carcinoma,basal cell carcinoma c.722C>T p.P241L 16:2058767-2058767 6
30 COSM147706701 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 6
31 COSM150353664 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 6
32 COSM151748023 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 6
33 COSM150576157 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 6
34 COSM149802478 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 6
35 COSM148980439 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 6
36 COSM90415129 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 6
37 COSM149800636 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 6
38 COSM148991757 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 6
39 COSM151753165 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 6
40 COSM151513825 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 6
41 COSM151371066 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 6
42 COSM148982237 TSC2 skin,NS,carcinoma,basal cell carcinoma c.679T>A p.C227S 16:2056674-2056674 6
43 COSM136628294 TSC2 skin,NS,carcinoma,basal cell carcinoma c.902C>T p.P301L 16:2058767-2058767 6
44 COSM110103971 TSC2 skin,NS,carcinoma,basal cell carcinoma c.568T>A p.C190S 16:2056674-2056674 6
45 COSM150583851 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 6
46 COSM102616914 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 6
47 COSM136618116 TSC2 skin,NS,carcinoma,basal cell carcinoma c.712T>A p.C238S 16:2056674-2056674 6
48 COSM110102044 TSC2 skin,NS,carcinoma,basal cell carcinoma c.1949C>T p.S650F 16:2071897-2071897 6
49 COSM150574866 TSC2 skin,NS,carcinoma,basal cell carcinoma c.2060C>T p.S687F 16:2071897-2071897 6
50 COSM102629996 TSC2 skin,NS,carcinoma,basal cell carcinoma c.869C>T p.P290L 16:2058767-2058767 6

Expression for Basal Cell Carcinoma 1

Search GEO for disease gene expression data for Basal Cell Carcinoma 1.

Pathways for Basal Cell Carcinoma 1

Pathways related to Basal Cell Carcinoma 1 according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1 12.4 SMO PTCH2 PTCH1
2
Show member pathways
12.29 SMO PTCH2 PTCH1
3
Show member pathways
12.22 SMO PTCH2 PTCH1
4
Show member pathways
11.94 SMO PTCH2 PTCH1
5
Show member pathways
11.82 SMO PTCH2 PTCH1
6 11.69 SMO RASA1 PTCH1
7 11.08 SMO PTCH1
8 11.08 SMO PTCH2 PTCH1
9 11 SMO PTCH1
10
Show member pathways
10.65 SMO PTCH2 PTCH1
11
Show member pathways
10.08 SMO PTCH2 PTCH1

GO Terms for Basal Cell Carcinoma 1

Cellular components related to Basal Cell Carcinoma 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 caveola GO:0005901 9.16 SMO PTCH1
2 endocytic vesicle membrane GO:0030666 8.96 SMO PTCH1
3 ciliary membrane GO:0060170 8.62 SMO PTCH1

Biological processes related to Basal Cell Carcinoma 1 according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 epidermis development GO:0008544 9.57 PTCH2 PTCH1
2 vasculogenesis GO:0001570 9.56 SMO RASA1
3 pattern specification process GO:0007389 9.55 SMO PTCH1
4 heart morphogenesis GO:0003007 9.54 SMO PTCH1
5 embryonic organ development GO:0048568 9.52 SMO PTCH1
6 dorsal/ventral pattern formation GO:0009953 9.51 SMO PTCH1
7 negative regulation of smoothened signaling pathway GO:0045879 9.49 PTCH2 PTCH1
8 cellular response to cholesterol GO:0071397 9.48 SMO PTCH1
9 cell fate determination GO:0001709 9.46 PTCH2 PTCH1
10 somite development GO:0061053 9.43 SMO PTCH1
11 commissural neuron axon guidance GO:0071679 9.4 SMO PTCH1
12 mammary gland epithelial cell differentiation GO:0060644 9.37 SMO PTCH1
13 dorsal/ventral neural tube patterning GO:0021904 9.32 SMO PTCH1
14 smooth muscle tissue development GO:0048745 9.26 SMO PTCH1
15 positive regulation of epidermal cell differentiation GO:0045606 9.16 PTCH2 PTCH1
16 smoothened signaling pathway GO:0007224 9.13 SMO PTCH2 PTCH1
17 epidermal cell fate specification GO:0009957 8.62 PTCH2 PTCH1

Molecular functions related to Basal Cell Carcinoma 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 patched binding GO:0005113 9.26 SMO PTCH1
2 hedgehog family protein binding GO:0097108 9.16 PTCH2 PTCH1
3 hedgehog receptor activity GO:0008158 8.96 PTCH2 PTCH1
4 smoothened binding GO:0005119 8.62 PTCH2 PTCH1

Sources for Basal Cell Carcinoma 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....